Fangqiong Hu
Overview
Explore the profile of Fangqiong Hu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen H, Chen F, Hu F, Li Y, Zhang M, Zhou Q, et al.
Acta Biomater
. 2023 Jun;
167:401-415.
PMID: 37330028
MicroRNAs play a crucial role in regulating cartilage extracellular matrix (ECM) metabolism and are being explored as potential therapeutic targets for osteoarthritis (OA). The present study indicated that microRNA-224-5p (miR-224-5p)...
2.
Chen H, Ye T, Hu F, Chen K, Li B, Qiu M, et al.
Sci Adv
. 2023 Jun;
9(24):eadf0988.
PMID: 37315130
Osteoarthritis (OA) is the most common degenerative joint disease in the world. Gene therapy based on delivering microRNAs (miRNAs) into cells has potential for the treatment of OA. However, the...
3.
Li B, Ding T, Chen H, Li C, Chen B, Xu X, et al.
Bone Joint Res
. 2023 Jan;
12(1):33-45.
PMID: 36642417
Aims: Circular RNA (circRNA) is involved in the regulation of articular cartilage degeneration induced by inflammatory factors or oxidative stress. In a previous study, we found that the expression of...
4.
Wang J, Hu F, Yu P, Wang J, Liu Z, Bao Q, et al.
J Cancer Res Clin Oncol
. 2022 Nov;
149(8):5127-5138.
PMID: 36348018
Purpose: Although undergoing conventional chemotherapy significantly improves the prognosis of Osteosarcoma, chemoresistance and failure of therapy is still a significant challenge. Furthermore, conventional chemotherapy, like doxorubicin, would upregulate the expression...
5.
Wang H, Liu Z, Wang J, Hu F, Zhou Q, Wei L, et al.
Front Med
. 2022 Nov;
16(6):883-895.
PMID: 36334211
Metastasis and drug resistance are the leading causes of poor prognosis in patients with osteosarcoma. Identifying the relevant factors that drive metastasis and drug resistance is the key to improving...
6.
Liu Z, Wen J, Hu F, Wang J, Hu C, Zhang W
Cancer Sci
. 2021 Dec;
113(2):432-445.
PMID: 34927311
Thrombospondin-1 (TSP1) is generally assumed to suppress the growth of osteosarcoma through inhibiting angiogenesis; however, it is unclear whether TSP1 could affect the antitumor immunity against osteosarcoma. We aimed to...
7.
Li B, Chen K, Qian N, Huang P, Hu F, Ding T, et al.
J Cell Mol Med
. 2021 May;
25(11):5283-5294.
PMID: 33939310
Osteoarthritis (OA) is one of the most frequent chronic joint diseases with the increasing life expectancy. The main characteristics of the disease are loss of articular cartilage, subchondral bone sclerosis...
8.
Liu Z, Wang H, Hu C, Wu C, Wang J, Hu F, et al.
Cell Death Dis
. 2021 Feb;
12(2):164.
PMID: 33558476
In this study, we identified the multifaceted effects of atezolizumab, a specific monoclonal antibody against PD-L1, in tumor suppression except for restoring antitumor immunity, and investigated the promising ways to...
9.
Liu Z, Li C, Huang P, Hu F, Jiang M, Xu X, et al.
Front Cell Dev Biol
. 2021 Jan;
8:594785.
PMID: 33425899
Tumor necrosis factor-alpha (TNF-α) promotes osteoclasts differentiation to enhance bone resorption and inhibits osteoblasts differentiation to impair bone formation, which plays a central role in the development of postmenopausal osteoporosis...
10.
Wang J, Hu C, Wang J, Shen Y, Bao Q, He F, et al.
J Immunother
. 2019 Jun;
42(9):321-330.
PMID: 31219973
The aim of this study was to provide a basis for the theory that the combination of conventional chemotherapy and immunotherapy would be an effective treatment for osteosarcoma. Here, the...